Reply from authors re: Stacy Loeb. Use of baseline prostate-specific antigen measurements to personalize prostate cancer screening. Eur Urol 2012;61:875-6

摘要

We thank Loeb for the positive and insightful editorial [1] regarding our study on prostate-specific antigen (PSA) for long-term prediction of prostate cancer (PCa) incidence and mortality [2]. We fully agree that our data strongly support the use of personalized PSA screening rather than a "one size fits all" approach.As also pointed out by Loeb, major strengths of our study include that screening for PCa is not recommended in Denmark and that, in subanalyses, we studied the period 1981-1995, before PSA testing was available in Denmark. Thus in our study, a diagnosis of PCa was not a result of PSA-based screening but rather was based on clinical symptoms leading to further examination and subsequent diagnosis.